MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymthe.2024.03.034

Медицинская библиотека · Molecular therapy : the journal of the American Society of Gene Therapy · 2024

Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.

Herstine Jessica A, Chang Pi-Kai, Chornyy Sergiy, Stevenson Tamara J, Sunshine Alex C, Nokhrina Ksenia, Rediger Jessica, Wentz Julia, Vetter Tatyana A, Scholl Erika, Holaway Caleb, Pyne Nettie K, Bratasz Anna, Yeoh Stewart, Flanigan Kevin M, Bonkowsky Joshua L, Bradbury Allison M

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

Leukoencephalopathy with vanishing white matter (VWM) is a progressive incurable white matter disease that most commonly occurs in childhood and presents with ataxia, spasticity, neurological degeneration, seizures, and premature death. A distinctive feature is episodes of rapid neurological deterioration provoked by stressors such as infection, seizures, or trauma. VWM is caused by autosomal recessive mutations in one of five genes that encode the eukaryotic initiation factor 2B complex, which is necessary for protein translation and regulation of the integrated stress response. The majority of mutations are in EIF2B5. Astrocytic dysfunction is central to pathophysiology, thereby constituting a potential therapeutic target. Herein we characterize two VWM murine models and investigate astrocyte-targeted adeno-associated virus serotype 9 (AAV9)-mediated EIF2B5 gene supplementation therapy as a therapeutic option for VWM. Our results demonstrate significant rescue in body weight, motor function, gait normalization, life extension, and finally, evidence that gene supplementation attenuates demyelination. Last, the greatest rescue results from a vector using a modified glial fibrillary acidic protein (GFAP) promoter-AAV9-gfaABC(1)D-EIF2B5-thereby supporting that astrocytic targeting is critical for disease correction. In conclusion, we demonstrate safety and early efficacy through treatment with a translatable astrocyte-targeted gene supplementation therapy for a disease that has no cure.

Для цитирования: Herstine Jessica A, Chang Pi-Kai, Chornyy Sergiy, Stevenson Tamara J, Sunshine Alex C, Nokhrina Ksenia, Rediger Jessica, Wentz Julia, Vetter Tatyana A, Scholl Erika, Holaway Caleb, Pyne Nettie K, Bratasz Anna, Yeoh Stewart, Flanigan Kevin M, Bonkowsky Joshua L, Bradbury Allison M. Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.. Molecular therapy : the journal of the American Society of Gene Therapy. 2024. DOI: 10.1016/j.ymthe.2024.03.034.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.